Dr. Robin C. Ryther, MD
Neurology (Epilepsy Physician)
At a glance
- Medical school
- Texas Tech University Health Science Center School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Texas Tech University Health Science Center School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Epilepsy Physician primary
MO license 2011011565 -
Clinical Neurophysiology Physician
MO license 2011011565 -
Neurology with Special Qualifications in Child Neurology Physician
MO license 2011011565
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Louis Childrens Hospital Saint Louis, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levetiracetam Other prescribers in Saint Louis, MO | 25 |
| Lacosamide Other prescribers in Saint Louis, MO | 14 |
| Rufinamide | 12 |
| Felbamate | 11 |
| Levocarnitine | 11 |
| Levocarnitine (levocarnitine (with sugar)) | 11 |
| Valproic Acid (valproic acid (as sodium salt)) Other prescribers in Saint Louis, MO | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $113,120 in research payments for these studies, mostly to the institutions running them.
- Open-Label Extension Study of Trofinetide for Rett Syndrome
Acadia Pharmaceuticals Inc · Terminated · NCT04776746
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.